Curis, Inc. (NASDAQ:CRIS) Q2 2024 Earnings Conference Call August 1, 2024 8:30 AM ET

Company Participants

Diantha Duvall - Chief Financial Officer
Jim Dentzer - President and CEO
Jonathan Zung - Chief Development Officer

Conference Call Participants

Yale Jen - Laidlaw
Ed White - H.C. Wainwright
Soumit Roy - JonesTrading
Li Watsek - Cantor

Operator

Good morning, ladies and gentlemen. And welcome to the Curis Provides Second Quarter 2024 Business Update Conference Call. At this time, all lines are in listen-only mode. Following the presentation, we will conduct a question-and-answer session. [Operator Instructions]

This call is being recorded on Thursday, August 1, 2024. I would now like to turn the conference over to Diantha Duvall. Please go ahead.

Diantha Duvall

Thank you and welcome to Curis’ second quarter 2024 business update call. Before we begin, I would like to encourage everyone to go to the Investor section of our website at www.curis.com to find our second quarter 2024 business update press release and related financial tables.

I would also like to remind everyone that during the call, we will be making forward-looking statements, which are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and actual results may differ materially. For additional details, please see our SEC filings.

Joining me on today’s call are Jim Dentzer, President and Chief Executive Officer; and Jonathan Zung, Chief Development Officer. We will also be available for a question-and-answer period at the end of the call. I’d now like to turn the call over to Jim.

Jim Dentzer

Thank you, Diantha. Good morning, everyone, and welcome to Curis’ second quarter business update call. Let’s start with our TakeAim Lymphoma study, which is evaluating emavusertib in combination with ibrutinib in relapsed/refractory PCNSL patients that have failed after treatment with a BTK inhibitor. These patients have generally seen methotrexate chemo and radiation in the front-line setting, followed by ibrutinib in the second line.

As patients progress on ibrutinib, they’re eligible to enroll into our study where we add emavusertib to their ibrutinib regimen. The scientific thesis for this combination is that blocking both of the pathways driving NHL, the TLR pathway with emavusertib and the BCR pathway with ibrutinib, can enable patients to achieve an objective response even after they have progressed on ibrutinib in monotherapy.

We presented data for the first five patients in this study at the ASH conference last December, where we reported an objective response rate over 50%. These data were early but very encouraging, especially given the high unmet need in this population.